beta-Amanitin is an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, but not RNA polymerase I or bacterial RNA polymerase. It inhibits mammalian protein synthesis. These properties make it interesting as a new potential drug for ADC research. α-Amanitin is already known as effective payload for ADCs. beta-Amanitin has a comparable biological activity but in addition it has a carboxy group, suitable for coupling reactions.

ADC technology offers a wide potential for the future and Cfm Oskar Tropitzsch GmbH supplies besides beta-Amanitin many other payloads for antibody drug conjugation (ADC).